{"id":37182,"date":"2025-07-11T15:00:16","date_gmt":"2025-07-11T07:00:16","guid":{"rendered":"https:\/\/flcube.com\/?p=37182"},"modified":"2025-07-11T15:00:17","modified_gmt":"2025-07-11T07:00:17","slug":"zhimeng-biopharmas-cb03-154-receives-cde-approval-for-als-phase-ii-iii-clinical-study","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37182","title":{"rendered":"Zhimeng Biopharma&#8217;s CB03-154 Receives CDE Approval for ALS Phase II\/III Clinical Study"},"content":{"rendered":"\n<p>China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II\/III clinical study for its next-generation KCNQ2\/3 potassium channel opener CB03-154 in amyotrophic lateral sclerosis (ALS) following approval from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA).<\/p>\n\n\n\n<p><strong>ALS: A Severe Neurodegenerative Disease<\/strong><br>ALS is a severe neurodegenerative disease characterized by the disruption, damage, or destruction of nerve cells in the brain and spinal cord, ultimately leading to loss of muscle control. While the exact cause of ALS remains unclear, research indicates that it is closely linked to ion channel dysfunction, impaired synaptic transmission, and neuronal excitation-inhibition imbalance.<\/p>\n\n\n\n<p><strong>CB03-154: A Promising Therapeutic Approach<\/strong><br>CB03-154 is a novel KCNQ2\/3 potassium channel opener that features high ion channel selectivity, excellent chemical and metabolic stability, strong anti-neuronal hyperexcitability activity, and favorable pharmacokinetic and safety profiles. It has shown potential in treating various central nervous system (CNS) disorders, including ALS, epilepsy, major depressive disorder (MDD), and others. Preclinical studies have demonstrated that CB03-154 significantly reduces motor neuron hyperexcitability in ALS models, slows the deterioration of muscle strength-related functional parameters, delays disease onset, extends survival, and normalizes muscle and neuronal morphology.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II\/III clinical study&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37183,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1096],"class_list":["post-37182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-zhimeng-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhimeng Biopharma&#039;s CB03-154 Receives CDE Approval for ALS Phase II\/III Clinical Study - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II\/III clinical study for its next-generation KCNQ2\/3 potassium channel opener CB03-154 in amyotrophic lateral sclerosis (ALS) following approval from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37182\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhimeng Biopharma&#039;s CB03-154 Receives CDE Approval for ALS Phase II\/III Clinical Study\" \/>\n<meta property=\"og:description\" content=\"China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II\/III clinical study for its next-generation KCNQ2\/3 potassium channel opener CB03-154 in amyotrophic lateral sclerosis (ALS) following approval from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37182\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-11T07:00:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-11T07:00:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1109.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37182#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37182\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhimeng Biopharma&#8217;s CB03-154 Receives CDE Approval for ALS Phase II\\\/III Clinical Study\",\"datePublished\":\"2025-07-11T07:00:16+00:00\",\"dateModified\":\"2025-07-11T07:00:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37182\"},\"wordCount\":217,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37182#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1109.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Zhimeng Biopharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37182#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37182\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37182\",\"name\":\"Zhimeng Biopharma's CB03-154 Receives CDE Approval for ALS Phase II\\\/III Clinical Study - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37182#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37182#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1109.webp\",\"datePublished\":\"2025-07-11T07:00:16+00:00\",\"dateModified\":\"2025-07-11T07:00:17+00:00\",\"description\":\"China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II\\\/III clinical study for its next-generation KCNQ2\\\/3 potassium channel opener CB03-154 in amyotrophic lateral sclerosis (ALS) following approval from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37182#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37182\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37182#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1109.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1109.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zhimeng Biopharma's CB03-154 Receives CDE Approval for ALS Phase II\\\/III Clinical Study\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37182#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhimeng Biopharma&#8217;s CB03-154 Receives CDE Approval for ALS Phase II\\\/III Clinical Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhimeng Biopharma's CB03-154 Receives CDE Approval for ALS Phase II\/III Clinical Study - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II\/III clinical study for its next-generation KCNQ2\/3 potassium channel opener CB03-154 in amyotrophic lateral sclerosis (ALS) following approval from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37182","og_locale":"en_US","og_type":"article","og_title":"Zhimeng Biopharma's CB03-154 Receives CDE Approval for ALS Phase II\/III Clinical Study","og_description":"China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II\/III clinical study for its next-generation KCNQ2\/3 potassium channel opener CB03-154 in amyotrophic lateral sclerosis (ALS) following approval from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA).","og_url":"https:\/\/flcube.com\/?p=37182","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-11T07:00:16+00:00","article_modified_time":"2025-07-11T07:00:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1109.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37182#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37182"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhimeng Biopharma&#8217;s CB03-154 Receives CDE Approval for ALS Phase II\/III Clinical Study","datePublished":"2025-07-11T07:00:16+00:00","dateModified":"2025-07-11T07:00:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37182"},"wordCount":217,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37182#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1109.webp","keywords":["Clinical trial approval \/ initiation","Zhimeng Biopharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37182#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37182","url":"https:\/\/flcube.com\/?p=37182","name":"Zhimeng Biopharma's CB03-154 Receives CDE Approval for ALS Phase II\/III Clinical Study - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37182#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37182#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1109.webp","datePublished":"2025-07-11T07:00:16+00:00","dateModified":"2025-07-11T07:00:17+00:00","description":"China-based Shanghai Zhimeng Biopharma, Inc. is set to carry out a Phase II\/III clinical study for its next-generation KCNQ2\/3 potassium channel opener CB03-154 in amyotrophic lateral sclerosis (ALS) following approval from the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37182#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37182"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37182#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1109.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1109.webp","width":1080,"height":608,"caption":"Zhimeng Biopharma's CB03-154 Receives CDE Approval for ALS Phase II\/III Clinical Study"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37182#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhimeng Biopharma&#8217;s CB03-154 Receives CDE Approval for ALS Phase II\/III Clinical Study"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1109.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37182"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37182\/revisions"}],"predecessor-version":[{"id":37184,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37182\/revisions\/37184"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37183"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}